These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 9427768

  • 21. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Tofanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M.
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [Abstract] [Full Text] [Related]

  • 22. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [Abstract] [Full Text] [Related]

  • 23. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.
    Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, Kikui M, Ohno A, Fukuoka M, Kawase I.
    Clin Cancer Res; 1997 Oct; 3(10):1831-5. PubMed ID: 9815570
    [Abstract] [Full Text] [Related]

  • 24. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E.
    Anticancer Res; 1999 Oct; 19(4C):3613-8. PubMed ID: 10629660
    [Abstract] [Full Text] [Related]

  • 25. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, Jones RT, Borkowski A, Caporaso NA, Fleming M, Trastek V, Pairolero P, Tazelaar H, Midthun D, Jett JR, Liotta LA, Travis WD, Harris CC.
    Clin Cancer Res; 2005 Jan 01; 11(1):232-41. PubMed ID: 15671551
    [Abstract] [Full Text] [Related]

  • 26. Prognostic significance of p53 status in non-small cell lung cancer in correlation with postoperative adjuvant therapy.
    Hanaoka N, Tanaka F, Wada H.
    Thorac Cardiovasc Surg; 2002 Dec 01; 50(6):355-9. PubMed ID: 12457313
    [Abstract] [Full Text] [Related]

  • 27. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
    Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H, Ogura S, Shimizu M, Katoh H, Kawakami Y.
    Clin Cancer Res; 2000 Oct 01; 6(10):4073-81. PubMed ID: 11051259
    [Abstract] [Full Text] [Related]

  • 28. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
    Ralhan R, Nath N, Agarwal S, Mathur M, Wasylyk B, Shukla NK.
    Clin Cancer Res; 1998 Sep 01; 4(9):2147-52. PubMed ID: 9748133
    [Abstract] [Full Text] [Related]

  • 29. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma.
    Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T.
    Surgery; 2003 May 01; 133(5):486-94. PubMed ID: 12773976
    [Abstract] [Full Text] [Related]

  • 30. p53 protein expression in squamous cell carcinoma of the vulva.
    Scheistrøen M, Tropé C, Pettersen EO, Nesland JM.
    Cancer; 1999 Mar 01; 85(5):1133-8. PubMed ID: 10091798
    [Abstract] [Full Text] [Related]

  • 31. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
    Sitruk V, Vaysse J, Chevret S, Ganne-Carrie N, Christidis C, Trinchet J, Beaugrand M.
    Gastroenterol Clin Biol; 2000 Dec 01; 24(12):1159-63. PubMed ID: 11173728
    [Abstract] [Full Text] [Related]

  • 32. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
    Bozcuk H, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Ozbudak IH, Artac M, Ozdogan M, Samur M, Kaya A, Savas B.
    Med Sci Monit; 2005 Jun 01; 11(6):HY11-20. PubMed ID: 15917726
    [Abstract] [Full Text] [Related]

  • 33. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
    Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L.
    Breast Cancer Res Treat; 2005 Sep 01; 93(2):111-5. PubMed ID: 16187230
    [Abstract] [Full Text] [Related]

  • 34. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, Tsubota N.
    Ann Thorac Surg; 2004 Sep 01; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [Abstract] [Full Text] [Related]

  • 35. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
    Gottschlich S, Folz BJ, Goeroegh T, Lippert BM, Maass JD, Werner JA.
    Anticancer Res; 1999 Sep 01; 19(4A):2703-5. PubMed ID: 10470224
    [Abstract] [Full Text] [Related]

  • 36. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.
    Mitsudomi T, Hamajima N, Ogawa M, Takahashi T.
    Clin Cancer Res; 2000 Oct 01; 6(10):4055-63. PubMed ID: 11051256
    [Abstract] [Full Text] [Related]

  • 37. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis.
    Pappot H, Francis D, Brünner N, Grondahl-Hansen J, Osterlind K.
    Clin Cancer Res; 1996 Jan 01; 2(1):155-60. PubMed ID: 9816102
    [Abstract] [Full Text] [Related]

  • 38. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
    Murray PV, Soussi T, O'Brien ME, Smith IE, Brossault S, Norton A, Ashley S, Tavassoli M.
    Br J Cancer; 2000 Dec 01; 83(11):1418-24. PubMed ID: 11076647
    [Abstract] [Full Text] [Related]

  • 39. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
    Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M, Tanimoto M.
    Anticancer Res; 2003 Dec 01; 23(3C):2829-36. PubMed ID: 12926120
    [Abstract] [Full Text] [Related]

  • 40. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
    Tsubochi H, Sato N, Hiyama M, Kaimori M, Endo S, Sohara Y, Imai T.
    Ann Thorac Surg; 2006 Oct 01; 82(4):1198-204. PubMed ID: 16996907
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.